超低分子化合物K对多发性骨髓瘤的治疗作用和分子机制
Young Eun Lee1, Jin Young Kim2, Hye Ran Kim2
1Department of Laboratory Medicine, Chonnam National University Medical School and Chonnam National University Hwasun Hospital, Hwasun, Republic of Korea; KBlueBio, Inc., Hwasun, Republic of Korea.
一种新型化合物,KBB-N1,通过增加化p53.3,显示出治疗多发性骨髓瘤 (MM) 的前景. 这种超低分子量金氏化物化合物K具有极小的毒性,因此适合老年MM患者使用.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 多发性骨髓瘤 (MM) 是一种不可治愈的血细胞癌,主要影响60岁以上的人.
- 虽然新的治疗方法改善了MM的预后,但对于复发/耐药病例仍然存在挑战,特别是在年龄和药物毒性方面.
- 对于治疗多发性骨髓瘤的新型低毒性治疗剂的需求越来越大.
研究的目的:
- 为了评估KBB-N1的疗效,一个超低分子量金氏化物化合物K,在治疗多发性骨髓瘤.
- 研究KBB-N1的作用机制,特别是其对酸化p53表达的作用.
- 在临床前模型中评估KBB-N1的安全性和毒性概况.
主要方法:
- 这项研究涉及使用KBB-N1.1治疗多发性骨髓瘤模型.
- 分析了酸化p53的表达水平.
- 对造血干细胞和主要器官进行了毒性评估.
主要成果:
- KBB-N1证明了多发性骨髓瘤的有效治疗.
- 用KBB-N1治疗导致酸化p53.3的表达增加.
- KBB-N1对造血干细胞和主要器官的毒性最小.
结论:
- KBB-N1是多发性骨髓瘤的有效治疗剂.
- 该机制涉及对酸化p53.3的上调调节.
- 对于患有多发性骨髓瘤的老年患者来说,KBB-N1代表了一个有希望的,低毒性的治疗选择.
更多相关视频
07:24Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
Published on: December 13, 2018
05:32Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
Published on: January 7, 2019
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Drugs that Stabilize Microtubules
